<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02893527</url>
  </required_header>
  <id_info>
    <org_study_id>ICM-URC-2014/33</org_study_id>
    <nct_id>NCT02893527</nct_id>
  </id_info>
  <brief_title>Implementation and Evaluation of a Social Journey Accompanied in Breast Cancer Diagnosis (EPARS SEIN)</brief_title>
  <acronym>EPARS-SEIN</acronym>
  <official_title>Implementation and Evaluation of a Social Journey Accompanied for Women With Breast Cancer Diagnosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut du Cancer de Montpellier - Val d'Aurelle</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Cemka-Eval</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Institut du Cancer de Montpellier - Val d'Aurelle</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evaluate and compare the return to work rate at 12 months&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Evaluate and compare the return to work rate at 12 months (from J1C1 [first day of the first&#xD;
      adjuvant chemotherapy regimen]) between the &quot;intervention&quot; group (which has accompanied the&#xD;
      career) and the standard group course&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    An IDMC validated the premature termination of the study on 19/02/2016 for lack of inclusion,&#xD;
    with continuation of the FU initially planned for women included&#xD;
  </why_stopped>
  <start_date type="Actual">February 24, 2015</start_date>
  <completion_date type="Actual">December 2017</completion_date>
  <primary_completion_date type="Actual">December 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluate and compare the return to work rate</measure>
    <time_frame>through study completion, an average of 5 years</time_frame>
    <description>Evaluate and compare the return to work rate at 12 months (from J1C1 [first day of the first adjuvant chemotherapy regimen]) between the &quot;intervention&quot; group (which has accompanied the career) and the standard group course</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>describe the conditions of the resumption of work</measure>
    <time_frame>through study completion, an average of 5 years</time_frame>
    <description>The study will also allow to describe the conditions of the resumption of work in 12 months for the patients concerned and to compare these conditions between the 2 groups</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">11</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Group &quot;intervention&quot;</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Personalized coaching coordinated by a coordinating nurse on a shutdown period of 8 months (consecutive stops).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group &quot;standard&quot;</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>conventional support</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>personalized coaching</intervention_name>
    <description>personalized coaching coordinated by a coordinating nurse on a shutdown period of 8 months (consecutive stops).</description>
    <arm_group_label>Group &quot;intervention&quot;</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient major&gt; 18&#xD;
&#xD;
          -  Have a diagnosis of localized breast cancer requiring surgery immediately adjuvant&#xD;
             therapy sequence including chemotherapy and radiotherapy&#xD;
&#xD;
          -  Being more than 3 years of retirement at diagnosis&#xD;
&#xD;
          -  Have a work contract valid at the time of diagnosis (before surgery)&#xD;
&#xD;
          -  Do not practice a profession&#xD;
&#xD;
          -  Be in possession of his rights (excluding guardianship, curatorship)&#xD;
&#xD;
          -  Raise the general social security scheme and have rights to cash benefits in the&#xD;
             Languedoc-Roussillon region&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient minor&#xD;
&#xD;
          -  Patient diagnosed with metastatic breast cancer&#xD;
&#xD;
          -  Patients refusing to sign the consent&#xD;
&#xD;
          -  Patients do not have sufficient understanding of the French language&#xD;
&#xD;
          -  Patients for whom it is impossible to give clear information&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>William JACOT</last_name>
    <role>Study Chair</role>
    <affiliation>Institut régional du Cancer de Montpellier</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Institut réginal du Cancer de Montpellier</name>
      <address>
        <city>Montpellier</city>
        <zip>34298</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>August 29, 2016</study_first_submitted>
  <study_first_submitted_qc>September 1, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 8, 2016</study_first_posted>
  <last_update_submitted>August 7, 2020</last_update_submitted>
  <last_update_submitted_qc>August 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 10, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

